Targeting oocyte maturation to improve fertility in older women.
Reproductive aging is an increasingly pressing problem facing women in modern society, due to delay in child bearing. According to Statistics Canada, 52% of all Canadian births in 2011 were by women aged 30 years and older, up from 24% in 1981 ( http://www.statcan.gc.ca/pub/91-209-x/2013001/article/11784-eng.htm ). Women older than 35 years of age experience significantly increased risks of infertility, miscarriage and congenital birth defects, mostly due to poor quality of the eggs. Increasingly sophisticated, and often invasive, assisted reproductive technologies (ARTs) have helped millions of women to achieve reproductive success. However, by and large, ARTs do not address the fundamental issue of reproductive aging in women: age-related decline in egg quality. More importantly, ARTs are not, and will never be, the main solution for the general population. Here, I attempt to review the scientific literature on age-related egg quality decline, based mostly on studies in mice and in humans. Emphasis is given to the brief period of time called oocyte maturation, which occurs just prior to ovulation. The rationale for this emphasis is that oocyte maturation represents a critical window where unfavorable ovarian conditions in older females contribute significantly to the decline of egg quality, and that science-based intervention during oocyte maturation represents the best chance of improving egg quality in older women. Finally, I summarize our own work in recent years on peri-ovulatory putrescine supplementation as a possible remedy for reproductive aging.
Ottawa Hospital Research Institute, The Ottawa Hospital - General Campus, 501 Smyth Road, Box 511, Ottawa, Ontario, K1H 8L6, Canada. jliu@ohri.ca.|Department of Obstetrics and Gynecology and Department of Biochemistry, Microbiology and Immunology (BMI), University of Ottawa, Ottawa, ON, Canada. jliu@ohri.ca.
X Johné
XJ
Liu
D000328:Adult; D000367:Age Factors; D000375:Aging; D000782:Aneuploidy; D000818:Animals; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy*; D009865:Oocytes / Q000166:cytology* / Q000473:pathology; D009866:Oogenesis; D010060:Ovulation; D011700:Putrescine / Q000627:therapeutic use
D011700:Putrescine
Aging; Aneuploidy; Histone deacetylation; Infertility; Oocyte maturation; Ornithine decarboxylase; Putrescine